SCHEMBL4425151

SCHEMBL4425151

CC(C)[C@H](NC(=O)OCc1ccccc1)C(=O)ON1C(=O)CCC1=O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSB P07858 5/20 0.53
CTSK P43235 4/20 0.53
CTSL P07711 4/20 0.53
CTSS P25774 4/20 0.52
CASP1 P29466 1/20 0.52
CASP3 P42574 1/20 0.52
CASP7 P55210 1/20 0.52
CASP6 P55212 1/20 0.52
CASP8 Q14790 1/20 0.52
CAPN1 P07384 3/20 0.51
CCR1 P32246 2/20 0.50
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
RAB9A P51151 1/20 0.49
ELANE P08246 1/20 0.47
PRTN3 P24158 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4039888 1.00 CTSB (0.53) CTSBCTSKCTSLCTSSCASP1
SCHEMBL10357140 1.00 CTSB (0.53) CTSBCTSKCTSLCTSSCASP1
SCHEMBL20529553 0.93 CTRB1 (0.48) CTSBCTSKCTSLCTSSCASP1
SCHEMBL25933042 0.92 CYP3A4 (0.48) CTSBCTSKCTSLCTSSCASP1
SCHEMBL2579674 0.90 CYP3A4 (0.62) CTSBCTSKCTSLCTSSCASP1
SCHEMBL10345811 0.88 CTSK (0.50) CTSBCTSKCTSLCTSSCASP1
SCHEMBL14366653 0.88 CTSK (0.50) CTSBCTSKCTSLCTSSCASP1
SCHEMBL4432276 0.88 CTSK (0.50) CTSBCTSKCTSLCTSSCASP1
SCHEMBL11799985 0.88 CTSB (0.47) CTSBCTSKCTSLCTSSCASP1
SCHEMBL11519751 0.87 CYP3A4 (0.45) CTSBCTSKCTSLCTSSCASP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4748843-A2 ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2026-05-27 EP disclosed
EP-4725560-A2 ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2026-04-15 EP disclosed
EP-4673474-A2 ANTI-PSMA ANTIBODIES, CONJUGATES, AND METHODS OF USE Eisai R&D Management Co., Ltd. (JP) 2026-01-07 EP disclosed
EP-4619037-A1 SMALL MOLECULE-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT Lerchen, Hans-Georg (DE) 2025-09-24 EP disclosed
US-20250242034-A1 PHOSPHORAMIDATE-BASED PSMA-TARGETED SMALL-MOLECULE DRUG CONJUGATES CANCER TARGETED TECH LLC (US) 2025-07-31 US disclosed
EP-4552654-A1 ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USE THEREOF Medilink Therapeutics (Suzhou) Co., Ltd. (CN) 2025-05-14 EP disclosed
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2025-03-27 US disclosed
EP-4472668-A1 PHOSPHORAMIDATE-BASED PSMA-TARGETED SMALL-MOLECULE DRUG CONJUGATES Cancer Targeted Technology LLC (US) 2024-12-11 EP disclosed
WO-2024242629-A1 MOLECULAR RADIOAFTERGLOW PROBES FOR CANCER RADIODYNAMIC THERANOSTICS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2024-11-28 WO disclosed
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2024-11-19 US disclosed
US-5142056-A Human immunodeficiency virus protease inhibitor ABBOTT LABORATORIES (US) 1992-08-25 US disclosed
EP-0480044-A1 NOVEL 4H-3,1-BENZOXAZIN-4-ONE DERIVATIVE Japan Tobacco Inc. (JP) 1992-04-15 EP disclosed
EP-0402646-A1 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1990-12-19 EP disclosed
EP-0167152-B1 PROTEASE ADSORBENT AND PROCESS FOR PURIFYING TPA UTILIZING THE SAME NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1990-11-14 EP disclosed
US-4708944-A Protease adsorbent and process for purifying TPA utilizing the same NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1987-11-24 US disclosed
EP-0167152-A2 Protease adsorbent and process for purifying TPA utilizing the same NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1986-01-08 EP disclosed
US-4341707-A CHEMICAL INTERMEDIATES; PEPTIDE SYNTHESIS Ogura, Haruo (JP) 1982-07-27 US disclosed
US-4250085-A PHOSPHONATE-CONTAINING OLIGOPEPTIDES, BACTERICIDES HOFFMANN-LA ROCHE INC. (US) 1981-02-10 US disclosed
EP-0002822-A1 Phosphorus containing peptide derivatives, their production, intermediates for their production and pharmaceutical compositions containing them F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) 1979-07-11 EP disclosed
US-4064270-A ANTHELMINTICS BAYER AKTIENGESELLSCHAFT (DT) 1977-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250242034-A1 PHOSPHORAMIDATE-BASED PSMA-TARGETED SMALL-MOLECULE DRUG CONJUGATES FOLH1, KLK3, ACP3 CTSB 447/4885CTSK 754/4885CTSL 755/4885
US-20250099600-A1 Active Metabolites of Kinesin Spindle Protein Inhibitor Conjugates KIF18B, KIF18A, KIF5B CTSB 3255/4885CTSK 2951/4885CTSL 3462/4885
US-12144865-B2 Antibody drug conjugates with enzymatically cleavable groups KIFC1, KIF2C, KIF5B CTSB 1614/4885CTSK 1510/4885CTSL 2116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.